Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases

Lingqian Li, Lei Huang, Henrique P. Lemos, Mario Mautino, Andrew L. Mellor

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The term "immune privilege" was coined to describe weak immunogenicity (hypo-immunity) that manifests in some transplant settings. We extended this concept to encompass hypo-immunity that manifests at local sites of inflammation relevant to clinical diseases. Here, we focus on emerging evidence that enhanced tryptophan catabolism is a key metabolic process that promotes and sustains induced immune privilege, and discuss the implications for exploiting this knowledge to improve treatments for hypo-immune and hyper-immune syndromes using strategies to manipulate tryptophan metabolism.

Original languageEnglish (US)
Article numberArticle 109
JournalFrontiers in Immunology
Volume3
Issue numberMAY
DOIs
StatePublished - Dec 1 2012

Fingerprint

Tryptophan
Chronic Disease
Immunity
Inflammation
Transplants
Therapeutics

Keywords

  • IDO
  • Immunity
  • Inflammation
  • Regulation
  • Tolerance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. / Li, Lingqian; Huang, Lei; Lemos, Henrique P.; Mautino, Mario; Mellor, Andrew L.

In: Frontiers in Immunology, Vol. 3, No. MAY, Article 109, 01.12.2012.

Research output: Contribution to journalReview article

Li, Lingqian ; Huang, Lei ; Lemos, Henrique P. ; Mautino, Mario ; Mellor, Andrew L. / Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. In: Frontiers in Immunology. 2012 ; Vol. 3, No. MAY.
@article{7d514431fe7a4e8c84f7b58cbc21117d,
title = "Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases",
abstract = "The term {"}immune privilege{"} was coined to describe weak immunogenicity (hypo-immunity) that manifests in some transplant settings. We extended this concept to encompass hypo-immunity that manifests at local sites of inflammation relevant to clinical diseases. Here, we focus on emerging evidence that enhanced tryptophan catabolism is a key metabolic process that promotes and sustains induced immune privilege, and discuss the implications for exploiting this knowledge to improve treatments for hypo-immune and hyper-immune syndromes using strategies to manipulate tryptophan metabolism.",
keywords = "IDO, Immunity, Inflammation, Regulation, Tolerance",
author = "Lingqian Li and Lei Huang and Lemos, {Henrique P.} and Mario Mautino and Mellor, {Andrew L.}",
year = "2012",
month = "12",
day = "1",
doi = "10.3389/fimmu.2012.00109",
language = "English (US)",
volume = "3",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases

AU - Li, Lingqian

AU - Huang, Lei

AU - Lemos, Henrique P.

AU - Mautino, Mario

AU - Mellor, Andrew L.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - The term "immune privilege" was coined to describe weak immunogenicity (hypo-immunity) that manifests in some transplant settings. We extended this concept to encompass hypo-immunity that manifests at local sites of inflammation relevant to clinical diseases. Here, we focus on emerging evidence that enhanced tryptophan catabolism is a key metabolic process that promotes and sustains induced immune privilege, and discuss the implications for exploiting this knowledge to improve treatments for hypo-immune and hyper-immune syndromes using strategies to manipulate tryptophan metabolism.

AB - The term "immune privilege" was coined to describe weak immunogenicity (hypo-immunity) that manifests in some transplant settings. We extended this concept to encompass hypo-immunity that manifests at local sites of inflammation relevant to clinical diseases. Here, we focus on emerging evidence that enhanced tryptophan catabolism is a key metabolic process that promotes and sustains induced immune privilege, and discuss the implications for exploiting this knowledge to improve treatments for hypo-immune and hyper-immune syndromes using strategies to manipulate tryptophan metabolism.

KW - IDO

KW - Immunity

KW - Inflammation

KW - Regulation

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84865286697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865286697&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2012.00109

DO - 10.3389/fimmu.2012.00109

M3 - Review article

VL - 3

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - MAY

M1 - Article 109

ER -